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Abstract
Background: The MAL2 gene, encoding a four-transmembrane protein of the MAL family, is amplified and
overexpressed in breast and other cancers, yet the significance of this is unknown. MAL-like proteins have
trafficking functions, but their molecular roles are largely obscure, partly due to a lack of known binding partners.
Methods: Yeast two-hybrid screening of a breast carcinoma cDNA expression library was performed using a
full-length MAL2 bait, and subsequent deletion mapping experiments were performed. MAL2 interactions were
confirmed by co-immunoprecipitation analyses and confocal microscopy was employed to compare protein sub-
cellular distributions. Sucrose density gradient centrifugation of membranes extracted in cold Triton X-100 was
employed to compare protein distributions between Triton X-100-soluble and -insoluble fractions.
Results: The tumor-associated protein mucin 1 (MUC1) was identified as a potential MAL2 partner, with MAL2/
MUC1 interactions being confirmed in myc-tagged MAL2-expressing MCF-10A cells using co-
immunoprecipitation assays. Deletion mapping experiments demonstrated a requirement for the first MAL2
transmembrane domain for MUC1 binding, whereas the MAL2 N-terminal domain was required to bind D52-like
proteins. Confocal microscopy identified cytoplasmic co-localisation of MUC1 and MAL2 in breast cell lines, and
centrifugation of cell lysates to equilibrium in sucrose density gradients demonstrated that MAL2 and MUC1
proteins were co-distributed between Triton X-100-soluble and -insoluble fractions. However co-
immunoprecipitation analyses detected MAL2/MUC1 interactions in Triton X-100-soluble fractions only. Myc-
MAL2 expression in MCF-10A cells was associated with both increased MUC1 detection within Triton X-100-
soluble and -insoluble fractions, and increased MUC1 detection at the cell surface.
Conclusion: These results identify MUC1 as a novel MAL2 partner, and suggest a role for MAL2 in regulating
MUC1 expression and/or localisation.
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Background
Human MAL2, a 19 kDa protein with four transmem-
brane (TM) domains [1,2] is a member of the MAL pro-
tein family. The founding member MAL [3] resides in
lipid rafts [4,5] and is required in apical vesicle transport
[6-9]. The MAL family also includes less characterised
members, including BENE, which is also a raft-associated
integral membrane protein [10], plasmolipin, a 20 kDa
proteolipid expressed in compact myelin and epithelial
cells [11] and chemokine-like factor superfamily 8
(CKLFSF8), a novel regulator of EGF-induced signalling
[12]. MAL2 was identified as a partner for tumor protein
D52-like proteins through yeast two-hybrid (Y2H) expres-
sion screening of a human breast carcinoma library [1].
The MAL2 protein is now known to be expressed in many
epithelial cell types, as well as peripheral neurons, mast
cells and dendritic cells [13]. In HepG2 hepatoma cells,
MAL2 resides exclusively within lipid rafts, and represents
an essential component for indirect basolateral-to-apical
transcytosis [2], where it shows a highly dynamic subcel-
lular localisation [14]. MAL2 has also been reported to be
distributed in both lipid raft and non-raft fractions in pri-
mary thyrocytes [15] and PC-3 prostate carcinoma cells
[16], predicting additional, uncharacterised cellular func-
tions for MAL2 outside lipid rafts.
The initial identification of MAL2 suggested its overex-
pression in breast cancer [1], which is supported by the
MAL2 gene being found at chromosome 8q24, which is
frequently gained in breast and other cancers [17]. Several
studies have now identified MAL2 amplification and/or
overexpression in breast cancer [18-22]. Overexpression
of MAL2 has also been reported in other cancers, includ-
ing primary ovarian carcinoma [23,24] and ascites [25],
and pancreatic carcinoma [26], where MAL2  has since
been employed as a discriminator of pancreatic carci-
noma versus chronic pancreatitis [27]. Expression profil-
ing has also indicated MAL2 overexpression in malignant
pleural mesothelioma of the epithelial type [28], and in
head and neck squamous cell carcinoma [29]. Immuno-
histochemical analyses first revealed differential MAL2
expression in renal carcinomas [15], with this being
recently confirmed in chromophobe renal cell carcinoma
versus oncocytoma [30].
Despite numerous reports of MAL2 overexpression in
breast cancer, little is known about how increased MAL2
expression may provide an advantage to cancer cells.
While MAL2 cellular localisation and function have been
explored in previous studies [2,14,15], the only known
MAL2 partners are members of the D52-like protein fam-
ily [1]. Interactions between MAL2 and both D52 and
D53 have since been identified in a large scale Y2H anal-
ysis [31], which supports further use of the Y2H system to
analyse MAL2 function. We therefore carried out a Y2H
screening of a breast carcinoma cDNA expression library
[1,32] to identify novel MAL2 binding partners. One pro-
tein thus identified was mucin 1 (MUC1), a transmem-
brane protein expressed on the apical surface of epithelial
cells [33] and overexpressed in multiple cancers [34], in
part through MUC1 gene amplification [35]. Like other
mucins, MUC1 protects and lubricates normal glandular
epithelia, whereas MUC1 overexpression in cancer alters
many cellular properties, including intercellular adhesion
and immune recognition [33,34]. As MUC1 therefore rep-
resented a candidate MAL2 partner of particular interest,
subsequent experiments were performed to confirm
MAL2/MUC1 interactions, and examine their significance
in breast epithelial and cancer cells. As we will describe,
this work identifies a MAL2 as a cytoplasmic MUC1 part-
ner which binds MUC1 in non-lipid raft fractions, and
may regulate MUC1 expression and/or subcellular distri-
bution.
Methods
Plasmid constructs
Bait proteins for use in the Y2H system were expressed
from the pAS2-1 vector (Clontech, Mountain View, Cali-
fornia, USA), and prey proteins were expressed from the
pACT2 (Clontech) or pAD-GAL4 (Stratagene, La Jolla, CA,
USA) vectors. The pAS2-1MAL2 bait construct was
obtained by subcloning an EcoRI-XhoI fragment, repre-
senting the entire MAL2 cDNA insert, into the EcoRI and
SalI  sites of pAS2-1 vector. For the pAS2-1MAL and
pACT2MAL constructs, a MAL cDNA insert was amplified
by PCR amplification to introduce a 5' NcoI site, and a 3'
XhoI site downstream of the stop codon, which was then
subcloned into the corresponding or compatible sites in
pAS2-1 and pACT2. Constructs including truncated ver-
sions of the MAL2 coding region were amplified by the
polymerase chain reaction (PCR) using specific primers
(Table 1). For the pAS2-1MAL2ΔN and pACT2 MAL2ΔN
constructs, primers introduced a 5' NcoI site, and a 3' XhoI
site downstream of the stop codon. For the pAS2-
1MAL2ΔNTM1, pAS2-1MAL2ΔNTM12, pAS2-
1MAL2ΔNTM123 and pAS2-1MAL2ΔNTM1234 con-
structs, primers introduced a 5' EcoRI site, and a 3' XhoI
site downstream of the stop codon. All subcloned con-
structs were verified by DNA sequencing, with PCR-gener-
ated inserts being fully sequenced on one DNA strand.
The pCR3.1/Myc-MAL2 expression construct has been
previously described [2]. All constructs encoding D52-like
fusion proteins, and the human breast carcinoma cDNA
library constructed in the HybriZAP vector (Stratagene)
have been previously described [1,32].
Yeast two-hybrid system and screening
Yeast cultures of the Saccharomyces cerevisiae Hf7c strain
were grown at 30°C in standard liquid or solid media,
based upon either rich YPD media (2% bacto-peptone,BMC Cell Biology 2009, 10:7 http://www.biomedcentral.com/1471-2121/10/7
Page 3 of 13
(page number not for citation purposes)
1% yeast extract, 2% dextrose), or minimal SD medium
(0.67% yeast nitrogen base without amino acids, 2% dex-
trose, with appropriate amino acid supplements) for
expression library screening and direct interaction testing.
For cDNA library expression screening, bait (pAS2-
1MAL2) and human breast carcinoma pAD-GAL4 library
plasmids were transfected simultaneously into Hf7c cells.
Subsequent screening and the recovery of plasmid DNA
from yeast cells were carried out as described [32]. For the
direct testing of interactions, paired baits (pAS2-1 con-
structs) and preys (pACT2 or pAD-GAL4 constructs) were
transfected into Hf7c cells as described [32]. Interactions
between baits and preys were assessed by qualitatively
determining HIS3 reporter gene activity [1].
Antibodies
The BC2 (an anti-MUC1 VNTR epitope mouse IgG1 mon-
oclonal) and FITC-BC2 antibodies have been previously
described [36]. Rabbit polyclonal c-Myc (A-14) and CAV1
antibodies were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA) and BD Biosciences (BD Bio-
sciences, San Jose, CA, USA), respectively. Affinity-
purified D52 rabbit polyclonal antibody has been
described previously [37]. Peroxidase-conjugated donkey
anti-rabbit and anti-mouse, FITC-conjugated donkey anti-
mouse and CY3-conjugated donkey anti-rabbit secondary
antibodies were purchased from Jackson ImmunoRe-
search, Inc (West Grove, PA, USA).
Preparation and affinity purification of polyclonal MAL2 
antisera
For the production of sheep antisera, one sheep was
injected subcutaneously with 2 mg coupled MAL2 C165-
P176 peptide antigen on 2 occasions, spaced by 3 weeks.
For the production of rabbit antisera, two rabbits were
injected subcutaneously with 0.5 mg coupled N13-V24 and
C165-P176 MAL2 peptide antigens on 2 occasions, spaced
by 2 weeks. Antisera were affinity-purified using relevant
MAL2 peptides as previously described [37].
Human breast cell lines
The MDA-MB-435 (a kind gift from Dr Janet Price, MD
Anderson Cancer Centre, Houston, TX), MDA-MB-453,
SK-BR-3 and MCF-7 breast cancer cells were cultured as
described in the American Type Culture Collection Cata-
logue. MCF-10A cells are described in the American Type
Culture Collection Catalogue and were cultured as
described [38].
Derivation of stably-transfected cell lines
The Myc-tagged MAL2 expression construct was stably
transfected into MCF-10A cells. Cells were seeded at
approximately 60% confluence in 100 mm dishes and
transfected 18 h later with 20 μg plasmid DNA using Lipo-
fectAMINE 2000 Reagent (Life Technologies, Inc., Gaith-
ersburg, MD, USA), according to the manufacturer's
instructions. After 24 h, G418 was added to a concentra-
tion of 1 mg/ml. Media were replenished every 2–3 days
and a G418-resistant mixed population was selected 14
days post-transfection. MDA-MB-435 and MDA-MB-453
breast cancer cells were transfected by electroporation
with a MUC1 cDNA containing 22 VNTR repeats in the
pcDNA3 vector (Invitrogen) or the vector alone. Stable
G418 resistant clones were isolated and MUC1 expression
determined by flow cytometry.
Preparation of total protein extracts and Western blot 
analyses
Cells were harvested in cold PBS, pelleted and washed
twice in cold PBS. Total cell protein extracts were prepared
by resuspending the pellet in SDS extraction buffer (125
mM Tris-HCl pH 6.8, 3% SDS, 5% 2-mercaptoethanol, 1
mM PMSF, and protease inhibitors [Roche, Basel, Switzer-
land]), which were then briefly sonicated. Samples were
Table 1: Deleted MAL2 yeast two-hybrid constructs, primer sequences and MAL2 regions deleted
Construct PCR Primer Sequences (5'-3') MAL2 region deleted
pAS2-1MAL2ΔN
pACT2MAL2ΔN
CATGCCATGGCCTACTCGGGCGCCTTCGTC
CCGCTCGAGTTACGGTCGCCATCTTCGTAA
amino acids
1–34
pAS2-1MAL2
ΔNTM1
CCGGAATTCTCCTCCAATGTTCCTCTACC
CCGCTCGAGTTACGGTCGCCATCTTCGTAA
amino acids
1–55
pAS2-1MAL2
ΔNTM12
CCGGAATTCCTCTCTGGAATGGTGGCT
CCGCTCGAGTTACGGTCGCCATCTTCGTAA
amino acids
1–86
pAS2-1MAL2
ΔNTM123
CCGGAATTCGAAGCAGCAGCCACATCC
CCGCTCGAGTTACGGTCGCCATCTTCGTAA
amino acids
1–119
pAS2-1MAL2
ΔNTM1234
CCGGAATTCGCTTTACGAAGATGGCGACCG
CCGCTCGAGTTACGGTCGCCATCTTCGTAA
amino acids
1–169BMC Cell Biology 2009, 10:7 http://www.biomedcentral.com/1471-2121/10/7
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resolved using SDS-PAGE on 12.5% polyacrylamide gels,
and electrotransferred to nitrocellulose filters (Millipore,
Billerica, MA, USA). Protein loading was analysed using
Ponceau S staining, and filters were blocked overnight at
4°C in 5% skim milk powder in TBS. Membranes were
washed twice with TBS and incubated with either affinity-
purified rabbit polyclonal MAL2 antisera (1/100), affin-
ity-purified rabbit polyclonal D52 antisera (1/100), BC2
(1/100) or CAV1 antibody (1/2000) in 0.1% Tween 20 in
TBS, for 2 h. Membranes were washed 3 times in 0.1%
Tween 20 in TBS, and then incubated with horseradish
peroxidase-conjugated donkey anti-rabbit or donkey anti-
mouse secondary antibody (Jackson ImmunoResearch,
Inc) (1/5000) for 2 h. Blots were washed 4 times with
0.1% Tween 20 in TBS, followed by 2 washes in TBS and
antigen-antibody complexes were visualised by Western
lightning chemiluminescent reagent (Perkin Elmer,
Waltham, Massachusetts, USA).
Co-immunoprecipitation analyses
MCF-10A cells were grown to 80% confluence in 100 mm
dishes and washed with cold PBS. For each co-immuno-
precipitation, proteins were extracted by scraping cells
from 6 dishes into 0.15 ml lysis buffer per dish. For co-
immunoprecipitation of MAL2 and D52 proteins, 10 mM
Tris with 1 mg/ml Saponin (Sigma-Aldrich, St. Louis, MO,
USA) was employed as a lysis buffer [39]. For co-immuno-
precipitation of MAL2 and MUC1 proteins, SDS lysis
buffer (125 mM Tris-HCl pH 6.8, 3% SDS, 5% 2-mercap-
toethanol, 1 mM PMSF, and protease inhibitors (Roche)
was employed. Protein A-Sepharose beads (Sigma-
Aldrich) plus rabbit MAL2 antisera (1/50), either alone or
with 1 μg/ml synthetic peptides N13-V24 and C165-P176, or
protein G-agarose beads (Sigma-Aldrich) plus BC2 (1/50)
were added to cell lysates and incubated on a rotary mixer
at 4°C for 16 h. Beads were washed 4 times with 1 ml lysis
buffer, followed by a final wash with PBS. Eluted proteins
(15 μl) were separated using SDS-PAGE on 12.5% poly-
acrylamide gels and electrotransferred to nitrocellulose fil-
ters (Millipore) for Western blot analyses, as above.
Immunofluorescent labelling of breast cell lines
Cell lines were cultured to near confluence, and harvested
by trypsinisation. Cells were diluted 3- to 10-fold and cul-
tured overnight on glass coverslips. For immunofluores-
cent staining, cells were washed twice with PBS, and fixed
in 4% paraformaldehyde supplemented with 0.1%
saponin for 20 min at RT. Cells were washed twice with
PBS, and incubated at RT for 2 h with affinity-purified rab-
bit MAL2 (1/50), D52 (1/100) antisera or mouse BC2-
FITC (40 μg/ml), in 0.1% bovine serum albumin (BSA) in
PBS. Primary antibody was omitted in control incuba-
tions. Cells were washed twice with PBS and incubated
with a CY3-conjugated donkey anti-rabbit secondary anti-
body (1/500) (Jackson ImmunoResearch) in 0.1% BSA in
PBS, for 1 h in the dark. Cells were washed again and DNA
was counterstained with 10 nM DAPI (Sigma-Aldrich).
Following 2 washes in PBS, cells were mounted in
DAPCO (Sigma-Aldrich) prepared according to the man-
ufacturer's instructions. Images were taken using a TCS
SP2 Laser Scanning Confocal microscope (Leica Technol-
ogies, Wetzlar, Germany), using a 63× oil-immersion
objective and a 4× zoom factor.
Membrane fractionation analyses
Triton X-100 soluble and insoluble fractions were pre-
pared essentially as described [40]. Cells grown in 4 × 100
mm dishes were treated with 20 mM methyl β-cyclodex-
trin (MβCD) at 37°C for 30 min. Cells were then rinsed
with PBS and lysed for 20 min in 1 ml 25 mM Tris-HCl pH
7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100 at 4°C.
The lysate was brought to 40% sucrose in a final volume
of 4 ml, placed at the bottom of a 12 ml tube, and then
layered with 6 ml 30% sucrose followed by 2 ml 5%
sucrose, made in the same buffer without Triton X-100.
Gradients were centrifuged for 22 h at 36,000 rpm at 4°C
in a Beckman SW41 rotor. Fractions of 1 ml were har-
vested from the top of the tube and aliquots were sub-
jected to Western blot analyses.
Results
Yeast two-hybrid screening identifies MUC1 as a putative 
MAL2 partner
To identify MAL2 partners expressed in breast cancer tis-
sue, a Y2H screen of a breast carcinoma cDNA expression
library [1,32] was performed with a full-length MAL2 bait.
Screening 5,000,000 cfu in Hf7c cells identified 72 Hf7c
colonies that remained His+ on restreaking on solid SD/-
Leu-Trp-His media. Sequencing the corresponding cDNA
inserts identified 6 novel candidate MAL2 binding part-
ners, of which MUC1 was most frequently isolated. DNA
sequencing indicated that all 7 MUC1 prey constructs
[preys #1–#7] encoded N-terminally truncated MUC1
proteins, which commonly included the SEA module, the
TM domain and the cytoplasmic tail (Figure 1a). Testing
whether MUC1 (prey#1, Figure 1a) could reproducibly
bind MAL2 and/or the related protein MAL showed that
MUC1 could bind both MAL2 and MAL baits in the Y2H
system (Figure 1b). In contrast, D52-like baits bound
MAL2 prey as previously reported [1], but not MAL (Fig-
ure 1b). Since MAL and MAL2 sequences differ in their N-
terminal regions [1] and a full-length MAL2 prey was orig-
inally isolated using a D54 bait [1], the MAL2 N-terminal
domain (M1-T34) was hypothesised to represent the inter-
action interface with D52-like proteins. Deleting this
region abolished interactions with all D52-like proteins
tested, but did not affect interactions with MUC1 (Figure
1b), suggesting that MUC1 and D52-like proteins bind
discrete regions of MAL2.BMC Cell Biology 2009, 10:7 http://www.biomedcentral.com/1471-2121/10/7
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Derivation of polyclonal antisera which specifically 
recognise MAL2 protein
To confirm MAL2/MUC1 interactions in other systems,
MAL2 antisera were generated in two species. Polyclonal
antisera were generated in sheep and targeted the MAL2
C-terminus (C165-P176). An N-terminal MAL2 peptide
(N13-V24) [2] as well as the C-terminus (C165-P176) were
also targeted for polyclonal antibody production in rabbit
[1]. Both peptide sequences are poorly conserved in other
MAL-like proteins [1]. Rabbit MAL2 antisera were
employed in Western blot analyses of total protein
extracts from a panel of human breast carcinoma cell
lines, as well as MCF-10A breast epithelial cells. A MAL2
species of the predicted molecular weight of 19 kDa was
detected in extracts from MDA-MB-435 and MDA-MB-
453 cell lines stably transfected with a MUC1 expression
vector (M) or the corresponding vector (V), and from
MCF-10A, SK-BR-3 and MCF-7 cells. This is in agreement
with previous detection of the 19 kDa MAL2 species in
other cell types [2,13]. Higher molecular weight MAL2
species were also detected (Figure 2), and are likely to rep-
resent glycosylated MAL2 forms [1,2,15].
Co-immunoprecipitation of MUC1 and MAL2 from MCF-
10A/Myc-MAL2 cells
Co-immunoprecipitation analyses were used to confirm
interactions between MAL2 and MUC1 proteins in MCF-
10A breast epithelial cells, stably-transfected with a Myc-
tagged MAL2 construct (MCF-10A/Myc-MAL2 cells). Pro-
tein extracts were immunoprecipitated with either MUC1,
c-Myc or MAL2 antisera, the latter in the absence or pres-
ence of MAL2 peptides. Immunoprecipitated proteins
were then subjected to Western blot analyses with MUC1,
MAL2, c-Myc and D52 antisera. These analyses demon-
strated that MUC1 monoclonal antibody immunoprecip-
itated MUC1 and co-immunoprecipitated MAL2, as
demonstrated by both MAL2 and c-Myc antisera, and that
c-Myc and MAL2 antisera immunoprecipitated MAL2 and
co-immunoprecipitated MUC1 (Figure 3). Interactions
between MUC1 and MAL2 proteins were also reproduci-
bly demonstrated in MCF-7 cells and MUC1-transfected
MDA-MB-435 cells (data not shown). As expected, D52
(a) Schematic diagram of MUC1 preys (prey#1-prey#7) iso- lated during Y2H screen Figure 1
(a) Schematic diagram of MUC1 preys (prey#1-
prey#7) isolated during Y2H screen. All prey proteins 
were predicted to include the SEA module, the 
transmembrane domain (TM) and the cytoplasmic 
tail (CT). The length of the extracellular tandem repeat is 
not shown to scale in full-length MUC1. (b) Deleting the 
MAL2 N-terminus does not affect its binding to MUC1 but 
abrogates its interaction with D52-like proteins. Interactions 
were tested between MAL, MAL2 or MAL2ΔN, and MUC1 
(prey#1) or D52-like proteins in Hf7c cells using the Y2H 
system. (-) indicates no detectable growth of co-transform-
ants on triple drop-out plates after 6–8 days at 30°C, (++) 
indicates growth after 3–4 days and (+++) indicates growth 
after 1–2 days. Identical results were obtained for all 3 D52-
like baits, which were grouped together in a single column. 
Results shown are representative of those obtained in 3 
independent experiments.
Extracellular domain
Prey #1 SEA CT
MUC1 SEA CT
Prey #2 SEA CT
Prey #3 SEA CT
Prey #5 SEA CT
Prey #6  SEA CT
Prey #7 SEA CT
Prey #4  SEA CT
a
b
- - - Vector -
+++ - - - MAL
++ - - MAL2
++ - MAL2 N
- - - ++ D52/D53/D54 -
MUC1
(Prey #1)
MAL Vector MAL2 Preys
Baits
MAL2 N
MAL2 antisera detect glycosylated and non-glycosylated  MAL2 forms in human breast cell lines, as indicated above  the top panel Figure 2
MAL2 antisera detect glycosylated and non-glyco-
sylated MAL2 forms in human breast cell lines, as 
indicated above the top panel. Total protein extracts 
were subjected to Western blot analysis using rabbit MAL2, 
D52 and MUC1 antisera, as indicated to the left of each 
panel. Sizes of detected proteins are indicated at the right. 
Results shown are representative of at least 3 independent 
experiments.
MDA-MB-435(V)
MDA-MB-435(M)
MDA-MB-453(V)
MDA-MB-453(M)
MCF-10A
SK-BR-3
MCF-7
MUC1 - 200 kDa
D52 - 26  kDa
MAL2
- 19 kDa 
- 40 kDa BMC Cell Biology 2009, 10:7 http://www.biomedcentral.com/1471-2121/10/7
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co-immunoprecipitated with MAL2 and c-Myc antisera,
and interestingly with MUC1 as well (Figure 3), suggest-
ing that MUC1 and D52 may form a multi-molecular
complex with MAL2. Inclusion of MAL2 peptide abol-
ished immunoprecipitation of MAL2 and co-immunopre-
cipitation of both MUC1 and D52 (Figure 3).
Mapping the MAL2 region required for MUC1 binding
The differential binding of D52-like proteins and MUC1
to MAL2ΔN and MAL (Figure 1b) suggested that D52 and
MUC1 bind different MAL2 domains. To map the MUC1
binding domain in MAL2, additional N-terminal MAL2
deletion mutants were constructed, to serially delete the
four MAL2 TM domains (Figure 4a). The TM domains
were specifically targeted as the MUC1 TM domain was
encoded by all prey constructs isolated (Figure 1a). Inter-
actions were detected between MUC1 prey and MAL2ΔN
bait, but not MAL2 bait additionally lacking the first TM
domain (MAL2ΔNTM1). Another putative MAL2 partner
identified through Y2H screening showed detectable
interactions with MAL2ΔNTM1, indicating that the lack of
MUC1 binding to MAL2ΔNTM1 was not artifactual (S.
Fanayan, unpublished results). These analyses therefore
indicate that the first MAL2 TM domain (Y35-S56) is
required for MUC1 binding (Figure 4b). Similar deletion
mapping experiments involving MUC1 indicated that the
minimal MAL2 binding region was contained within the
shortest MUC1 prey (prey #7) identified through yeast
two-hybrid screening (Figure 1a) (S. Fanayan, unpub-
lished results).
MAL2 and MUC1 co-localise in the cytoplasm of breast 
carcinoma cells
The intracellular localisation of MAL2 in breast cancer
cells was determined using indirect immunofluorescence
and confocal microscopy, and compared with that of
MUC1. As shown in Figure 5, SK-BR-3 and MUC1-overex-
pressing MDA-MB-435(M) cells showed punctate distri-
butions of MAL2 and MUC1 throughout the cell
cytoplasm, with partial co-localisation. In MCF-7 and
MDA-MB-453(M) cells, MAL2 was similarly detected
throughout the cytoplasm, while MUC1 was concentrated
towards the cell periphery, and showed only partial co-
localisation with MAL2. These results indicate that MAL2
and MUC1 co-localise within the cytoplasm, regardless of
the predominant site of MUC1 localisation. Furthermore,
MUC1 overexpression in MDA-MB-435 and MDA-MB-
453 cells did not alter MAL2 distribution in these cells
(Figure 5).
MAL2 and MUC1 are present in lipid raft fractions in 
human breast carcinoma cells
MAL2 has consistently been found in lipid raft-containing
membrane fractions in hepatoma HepG2 cells [2,14] as
well as in human thyroid epithelial cells [15]. We there-
fore examined the distribution of MAL2 and MUC1 in Tri-
ton X-100-soluble and -insoluble fractions from breast
carcinoma cell lines. Following centrifugation to equilib-
Co-immunoprecipitation analyses verifying interactions  between MAL2 and MUC1 Figure 3
Co-immunoprecipitation analyses verifying interac-
tions between MAL2 and MUC1. Total cell lysate from 
MCF-10A/Myc-MAL2 cells was immunoprecipitated with 
MUC1, c-Myc, or rabbit MAL2 antisera, either alone or with 
MAL2 peptides, as indicated above the top panel. Total cell 
lysate and immunoprecipitates were separated by SDS-PAGE 
and subjected to Western blot analyses with antisera against 
MUC1, MAL2, c-Myc and D52, as indicated at the left. Sizes 
of detected proteins are indicated at the right. Results shown 
are representative of at least 3 independent experiments.
Total cell
lysate
MUC1
c-Myc
MAL2
MAL2
+ Peptide
MUC1 - 200 kDa
MAL2 - 19 kDa
c-Myc - 40 kDa
D52 - 26 kDa
Immunoprecipitation
W
e
s
t
e
r
n
 
B
l
o
t
(a) Schematic representation of N-terminally-deleted MAL2  proteins (defined in Table 1) employed in Y2H analyses Figure 4
(a) Schematic representation of N-terminally-
deleted MAL2 proteins (defined in Table 1) 
employed in Y2H analyses. (b) Results of testing interac-
tions between full-length and deleted MAL2 bait proteins and 
MUC1 (prey#1) prey protein in Hf7c cells using the Y2H sys-
tem. (-) indicates no detectable growth of co-transformants 
on triple drop-out plates after 6–8 days incubation at 30°C 
while (++) indicates growth after 3–4 days. Results shown 
are representative of those obtained in 3 independent exper-
iments.
Bait
Prey
MAL2 MAL2
N
MAL2
NTM1
MAL2
NTM12
MAL2
NTM123
MAL2
NTM1234
V e c t o r - ---- -
MUC1
(Prey #1)
++ ++ - - - -
TM TM TM TM MAL2
TM TM TM TM MAL2 N
TM TM TM MAL2 NTM1
TM TM MAL2 NTM12
MAL2 NTM123 TM
MAL2 NTM1234
a
bBMC Cell Biology 2009, 10:7 http://www.biomedcentral.com/1471-2121/10/7
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rium in sucrose density gradients, the distributions of
MAL2 and MUC1 was compared in fractions 2–4, which
include Triton X-100-insoluble lipid rafts, and fractions
8–12, which include Triton X-100-soluble cytoplasmic
proteins and cell membranes. The distribution of the
MAL2 partner D52 was also determined, and compared
with that of caveolin-1 (CAV1), a known lipid raft protein
[16]. MUC1 was detected in both Triton X-100-soluble
and -insoluble fractions when endogenously expressed in
SK-BR-3 cells (Figure 6a) and exogenously expressed in
MDA-MB-435(M) (Figure 6c) and MDA-MB-453(M) cells
(Figure 6e), with MUC1 being predominantly detected in
lipid raft fractions in MDA-MB-453(M) cells (Figure 6e).
In MDA-MB-435(V) (Figure 6b) and MDA-MB-453(V)
cells (Figure 6d), MUC1 was weakly detected in soluble
fractions only. MAL2 was detected in both soluble and
insoluble fractions in all cell lines examined (Figure 6).
The D52 protein was predominantly detected in soluble
fractions but weakly detected in insoluble fractions in
most cell lines (Figure 6a, b–e). As expected, CAV1 was
exclusively detected in lipid raft fractions (Figure 6a and
data not shown).
The effect of cholesterol depletion on MUC1 and MAL2
distributions was examined by treating SK-BR-3 and
MDA-MB-435(M) cell lines with MβCD. In SK-BR-3 cells,
MβCD treatment rendered MUC1, MAL2 and CAV1 virtu-
ally undetectable in fractions 2–4 (Figure 7). The apparent
disappearance of CAV1 from SK-BR-3 fractions after
MβCD treatment is consistent with CAV1 expression
being reported as undetectable in whole SK-BR-3 cell
extracts [41,42]. In MDA-MB-435(M) cells, MβCD treat-
ment reduced MUC1, MAL2 and CAV1 detection in the
same fractions, which was accompanied by increased
detection in Triton X-100-soluble fractions (Figure 7), fur-
ther supporting co-distribution of MUC1 and MAL2
within lipid rafts. We then carried out (co)-immunopre-
cipitations of MUC1 and MAL2 from pooled soluble and
insoluble membrane fractions from MCF-10A/Myc-MAL2
cells. Both MAL2 and MUC1 were detected in insoluble
fractions (Figure 8a), yet MAL2 antisera co-immunopre-
cipitated MUC1 from pooled soluble fractions only (Fig-
ure 8b). The ability of MAL2 antisera to co-
immunoprecipitate MUC1 from fractions 5–8 despite low
MUC1 concentrations supports an association between
MAL2 and MUC1 in Triton X-100 soluble fractions.
Increased MAL2 expression leads to increased cell surface 
expression of MUC1
Interactions between MUC1 and MAL2, together with pre-
vious data showing MAL2 involvement in basolateral-to-
apical transport [2] suggested a role for MAL2 in localising
MUC1 to the cell surface. The effect of ectopic Myc-MAL2
expression on MUC1 subcellular localisation was there-
fore compared in parental and MCF-10A/Myc-MAL2 cells.
As shown in Figure 9a, MCF-10A/Myc-MAL2 cells showed
a dramatically elongated morphology relative to the
parental cell line, which did not reflect a change in differ-
entiation status, as assessed using neuronal and epithelial-
mesenchymal transition markers (data not shown).
Increased detection of glycosylated MAL2 in both raft and
non-raft fractions from MCF-10A/Myc-MAL2 cells was
also accompanied by increased MUC1 detection across all
membrane fractions (Figure 9c). Comparing the sub-cel-
lular localisations of these proteins using confocal micro-
MAL2 and MUC1 co-localise in the cytoplasm of breast carci- noma cell lines Figure 5
MAL2 and MUC1 co-localise in the cytoplasm of 
breast carcinoma cell lines. Indirect immunofluorescent 
analyses were carried out using the cell lines indicated to the 
left of each row, and MUC1 and sheep MAL2 antisera. MUC1 
antibody was identified as green color using a FITC-conju-
gated secondary antibody (left column) and MAL2 antisera 
was identified as red color using a Cy3-conjugated secondary 
antibody (middle column). Overlap between MUC1 and 
MAL2 proteins is shown as yellow in merged images (right 
column). Results shown represent those obtained from 3–4 
independent experiments.
Merge MAL2 MUC1
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Distribution of MUC1, MAL2 and D52 in membrane fractions from breast cancer cell lines Figure 6
Distribution of MUC1, MAL2 and D52 in membrane fractions from breast cancer cell lines. (a) SK-BR-3, (b) 
MDA-MB-435(V) (c) MDA-MB-435(M) (d) MDA-MB-453(V) and (e) MDA-MB-453(M) cells were extracted with 1% Triton 
X-100 at 4°C, and subjected to centrifugation to equilibrium in sucrose density gradients. Twelve 1 ml fractions (Fr, shown 
above each top panel) were collected from the top of the gradient and 15 μl aliquots from each were subjected to SDS-PAGE 
and Western blot analysis with antibodies against MUC1, MAL2 and D52, as indicated to the left of each panel. SK-BR-3 frac-
tions (a) were also immunoblotted with CAV1 antibody. In all panels, vertical lines between fractions 8 and 9 distinguish sam-
ples loaded on different gels. Sizes of detected proteins are indicated at the right. Results shown represent those obtained 
from 2–3 independent experiments.
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scopy revealed an accumulation of MUC1 at the periphery
of MCF-10A/Myc-MAL2 cells compared with parental
cells, which incompletely co-localised with MAL2 (Figure
9b). Taken together, these data show that ectopic Myc-
MAL2 expression in MCF-10A/Myc-MAL2 cells expands
the plasma membrane domain, and increases MUC1
detection at the cell periphery.
Discussion
MAL2 was first identified through its expression in breast
carcinoma and interactions with D52-like proteins within
the Y2H system [1]. We therefore undertook a Y2H screen
to identify MAL2 binding partners expressed in human
breast cancer tissue, which identified a number of novel
putative binding proteins, including MUC1. MUC1 repre-
sented a candidate partner of particular interest, given the
fact that it is overexpressed in cancer types where MAL2
overexpression has also been reported, and as MUC1
overexpression contributes to cancer progression through
a number of mechanisms [43,44]. Interactions between
human MUC1 and MAL2 proteins are also broadly con-
sistent with the previously reported interactions between
the yeast signalling mucin Msb2 and the tetraspanin pro-
tein Sho1 [45]. Subsequent results collectively identify
MAL2 as a novel cytoplasmic MUC1 partner, and a possi-
ble regulator of MUC1 expression and/or subcellular dis-
tribution. It is striking to note that MAL2, a chromosome
8q24 amplification target, has now been shown to bind
MUC1 and D52, both of which are amplified and/or over-
expressed in breast and other cancers [21,22,34,35,46]
strongly suggesting that these proteins have co-operating
functions in cancer cells.
While a recent study by Kinlough et al. [47] indicated that
palmitoylation is the dominant feature modulating
MUC1 recycling to the plasma membrane, the mecha-
nisms by which MUC1 is targeted and maintained at the
plasma membrane are not fully understood. Since ectopic
Myc-MAL2 expression in MCF-10A cells was associated
with increased MUC1 detection at the cell periphery in the
present study, MAL2 may play a direct or indirect role in
MUC1 targeting. Interestingly, MAL2 incompletely co-
localised with peripheral MUC1 in MCF-10A/Myc-MAL2
cells, which supports previous findings that altering MAL2
expression can alter cargo accumulation distant to the pre-
dominant site of MAL2 expression [2,14]. However,
ectopic Myc-MAL2 expression also produced an apparent
expansion of cell surface domains in MCF-10A cells,
which may also contribute to increased MUC1 detection
at the cell periphery. Similar observations have been made
Effect of MβCD treatment on MUC1 and MAL2 distribution in lipid raft fractions Figure 7
Effect of MβCD treatment on MUC1 and MAL2 distribution in lipid raft fractions. SK-BR-3 and MDA-MB-435(M) 
cells were treated (+Mβ), or not (-Mβ), with 20 mM MβCD, extracted with 1% Triton X-100 at 4°C, and subjected to sucrose 
gradient centrifugation. Twelve fractions of 1 ml (Fr, as shown above each top panel) were collected and 15 μl aliquots were 
subjected to SDS-PAGE and Western blot analysis with antibodies to MUC1, MAL2 or CAV1, as indicated at the left, with 
sizes of detected proteins indicated at the right. In all panels, vertical lines between fractions 8 and 9 distinguish samples loaded 
on different gels. In fractions 2–4, MUC1, MAL2 and CAV1 were not detected in SK-BR-3 cells, or were significantly reduced 
in MDA-MB-435 [M] cells following MβCD treatment. Results shown represent those obtained from 3 independent experi-
ments.
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in a previous study where MAL overexpression altered the
morphology of MDCK cells, by seemingly expanding api-
cal cell surface domains through increased apical delivery
[6]. Finally, we also noted that ectopic MAL2 expression
produced an increase in MUC1 detection across Triton X-
100-soluble and -insoluble protein fractions in MCF-10A/
Myc-MAL2 cells, indicating that Myc-MAL2 may posi-
tively regulate MUC1 expression. This may also lead to
increased peripheral MUC1 detection. While it remains to
be determined whether MAL2 can alter MUC1 distribu-
tion in other cell types, the broad expression of MAL2
within epithelia [13] is consistent with MAL2 contribut-
ing to MUC1 targetting under physiological conditions. It
will also be of interest to examine whether MAL2 can sim-
ilarly regulate MUC1 secretion.
If MAL2 similarly regulates MUC1 expression and/or dis-
tribution in cancer cells, increased MAL2 levels could alter
cancer cell biology in several ways. Increased MUC1 local-
isation at the cell surface could reduce intercellular adhe-
sion and promote invasiveness [44], and increased MAL2
expression would thus be expected to have adverse signif-
icance in cancer cells. Accordingly, MAL2  has been
included within a gene signature of poor prognosis in
breast cancer [48], and MAL2 overexpression was associ-
ated with resistance to doxorubicin therapy in breast can-
cer patients [49]. MAL2 overexpression might also reduce
cytoplasmic MUC1 accumulation, which has been indi-
cated to be an adverse finding in breast and ovarian carci-
nomas [50-52], tumor types which also overexpress MAL2
[20,24,25]. Interestingly, suppression of MUC1  expres-
sion in a pancreatic cancer cell line reduced these cells'
metastatic potential, and was accompanied by reduced
MAL2  levels [53]. Further direct analyses are therefore
Co-immunoprecipitation analyses to detect MAL2/MUC1  interactions in Triton X-100-soluble versus-insoluble frac- tions Figure 8
Co-immunoprecipitation analyses to detect MAL2/
MUC1 interactions in Triton X-100-soluble versus-
insoluble fractions. MCF-10A/Myc-MAL2 cells were 
extracted with 1% Triton X-100 at 4°C, and subjected 
to sucrose gradient centrifugation. Antisera employed 
in Western blot analyses are shown at the left, and sizes of 
detected proteins are shown at the right. (a) Fractions (Fr, 
as shown above the top panel) of 1 ml were collected, and 
aliquots from each were subjected to SDS-PAGE and West-
ern blot analysis with MUC1 and MAL2 antisera. Vertical 
lines between fractions 8 and 9 distinguish samples loaded on 
different gels. (b) Pooled fractions (fractions 1–4, which 
include lipid rafts, fractions 5–8 and fractions 9–12) were 
immunoprecipitated with MUC1 or MAL2 antisera either 
alone or with MAL2 peptides (+Pep), as shown at the top of 
the panel. Immunoprecipitates were separated by SDS-PAGE 
and subjected to Western blot analysis with MUC1 mono-
clonal antibody. Results shown represent those obtained 
from 3 independent experiments.
b
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Effect of ectopic Myc-MAL2 expression on MCF-10A cell  morphology and intracellular localisation of MUC1 Figure 9
Effect of ectopic Myc-MAL2 expression on MCF-10A 
cell morphology and intracellular localisation of 
MUC1. (a) MCF-10A and MCF-10A/Myc-MAL2 cells were 
grown in culture and their morphologies compared by light 
microscopy (X100 magnification). (b) MCF-10A and MCF-
10A/Myc-MAL2 cells were co-stained for MUC1 (left panel) 
and MAL2 (middle panel). Overlap between the MUC1 and 
MAL2 proteins are shown in merged images (right panel). 
Images shown are single horizontal x-y sections. (c) MCF-
10A and MCF-10A/Myc-MAL2 cells were extracted with 1% 
Triton X-100 at 4°C, and centrifuged to equilibrium in 
sucrose density gradients. Twelve fractions of 1 ml were col-
lected (Fr, as shown above each top panel), and aliquots 
were subjected to SDS-PAGE and Western blot analysis with 
MUC1, MAL2 or CAV1 antisera, as indicated at the left, with 
sizes of detected proteins indicated at the right. Vertical lines 
between fractions 8 and 9 distinguish samples loaded on dif-
ferent gels. Results shown represent those obtained from 3 
independent experiments.
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required to determine whether MAL2 and MUC1 levels
are positively correlated in cancer types commonly
expressing these proteins, and whether MAL2 expression
is significantly associated with cell surface expression of
MUC1 in cancer cells.
The present study also provides the first report that MUC1
localises within lipid raft fractions in breast carcinoma
cells, and raises the possibility that some of MUC1's sig-
nalling functions [43,44] may occur within lipid rafts. Pre-
vious studies reported that MUC1 in T-lymphocyte cell
lines was insoluble in cold Triton X-100 and associated
with low density membrane fractions [54,55], yet Kin-
lough et al. [47] showed MUC1 from MDCK cells was
fully soluble in Triton X-100. The reported differences in
MUC1 solubility may be due to cell specific differences in
membrane composition and their selectivity for deter-
gents, as reported by Schuck et al. [56], or alternatively
MUC1 may not reside in lipid rafts in all cell types. We
demonstrated associations between MUC1 and MAL2 in
Triton X-100 soluble fractions, in agreement with MUC1
and MAL2 being predominantly detected in non-raft frac-
tions in all cell lines analysed, which was also noted for
the MAL2 partner D52. While we were unable to deter-
mine whether MAL2 and MUC1 associate within lipid
rafts, our results indicate that MAL2 associates with MUC1
and potentially other proteins outside lipid raft mem-
brane microdomains, as indicated for other tetraspanins
[57], and highlights the fact that MAL2 may have inde-
pendent functions within and outside lipid rafts.
Our analysis of MAL2 partners has also indicated that
MAL2 may represent a multifunctional transmembrane
adaptor protein, capable of binding more than one part-
ner simultaneously. We noted that both MAL2 and D52
co-immunoprecipitated with MUC1 in the present study,
despite the fact that direct interactions between MUC1
and D52 were not detected in the Y2H system. Independ-
ent interaction domains for MAL2/MUC1 and MAL2/D52
binding were also indicated by the MAL2 N-terminal
domain being required to bind D52-like proteins, yet the
first TM domain was required for binding MUC1. Corre-
spondingly, D52-like proteins did not bind MAL, whose
N-terminal sequence is poorly conserved with respect to
that of MAL2 [1], yet MUC1 bound both MAL and MAL2
in the Y2H system. These results therefore predict shared
and isoform-specific functions for MAL-like proteins,
through shared and discrete binding partners.
Conclusion
This study has identified MAL2 as a novel cytoplasmic
MUC1 partner and a potential regulator of MUC1 subcel-
lular distribution. MAL2/MUC1 interactions were
detected in Triton X-100-soluble membrane fractions,
indicating that MAL2 has specific functions within non-
raft membrane compartments in breast cancer cells. Since
MAL2  is known to be amplified and overexpressed in
breast and other cancers, it is striking that MAL2 has now
been shown to bind two proteins, MUC1 and D52, which
are also amplified and/or overexpressed. Based on these
results, and a previous study highlighting the co-amplifi-
cation of MAL2 and D52 genes in breast cancer [21], it will
be interesting to examine whether MAL2 and MUC1 are
commonly amplified and overexpressed in breast cancer,
and whether MAL2 expression is significantly associated
with cell surface expression of MUC1.
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